Efficacy of isatuximab in combination with steroids for the treatment of relapsed/refractory multiple myeloma patients exhibiting only biochemical progression—A single center retrospective study
Abstract Objectives Isatuximab is approved for treatment of relapsed/refractory multiple myeloma (RRMM) with dexamethasone and carfilzomib or pomalidomide. Patients receiving these three‐drug regimens have exhibited more Grade ≥ 3 adverse events (AEs) compared to the two‐drug class combination of isatuximab and steroids alone. Thus, this single‐center retrospective study investigated the efficacy of isatuximab with dexamethasone and methylprednisolone (ISAdm) for RRMM patients showing only biochemical progression (BP) of their disease. Methods Twenty‐four RRMM patients exhibiting only BP were administered isatuximab at 10 mg/kg with dexamethasone once weekly for cycle 1 of a 28‐day cycle, followed by every other week for each cycle thereafter. Starting in cycle 2, oral methylprednisolone was added every other day stopping 48 h before and starting 48 h after each dexamethasone infusion. Results Overall response rate and clinical benefit rate were 63% and 79%, respectively. Progression free survival was 12.9 months. There were only 5 AEs of Grade ≥ 3 which included lymphocytopenia (13%), leukopenia (4%), and neutropenia (4%). No Grade ≥ 3 AE related to respiratory infection, anemia, or thrombocytopenia were reported. Conclusion This study shows that the two‐drug class combination of ISAdm is an effective and well tolerated treatment option for RRMM patients exhibiting only BP..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:111 |
|---|---|
| Enthalten in: |
European Journal of Haematology - 111(2023), 4, Seite 628-635 |
| Beteiligte Personen: |
Regidor, Bernard Sean [VerfasserIn] |
|---|
| Anmerkungen: |
© 2023 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. |
|---|
| Umfang: |
8 |
|---|
| doi: |
10.1111/ejh.14057 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY015529614 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY015529614 | ||
| 003 | DE-627 | ||
| 005 | 20231111151508.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231111s2023 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1111/ejh.14057 |2 doi | |
| 028 | 5 | 2 | |a 2023-11-11_EJH_2023_111_4.zip.xml |
| 035 | |a (DE-627)WLY015529614 | ||
| 035 | |a (WILEY)EJH14057 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 100 | 1 | |a Regidor, Bernard Sean |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Efficacy of isatuximab in combination with steroids for the treatment of relapsed/refractory multiple myeloma patients exhibiting only biochemical progression—A single center retrospective study |
| 264 | 1 | |c 2023 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2023 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. | ||
| 520 | |a Abstract Objectives Isatuximab is approved for treatment of relapsed/refractory multiple myeloma (RRMM) with dexamethasone and carfilzomib or pomalidomide. Patients receiving these three‐drug regimens have exhibited more Grade ≥ 3 adverse events (AEs) compared to the two‐drug class combination of isatuximab and steroids alone. Thus, this single‐center retrospective study investigated the efficacy of isatuximab with dexamethasone and methylprednisolone (ISAdm) for RRMM patients showing only biochemical progression (BP) of their disease. Methods Twenty‐four RRMM patients exhibiting only BP were administered isatuximab at 10 mg/kg with dexamethasone once weekly for cycle 1 of a 28‐day cycle, followed by every other week for each cycle thereafter. Starting in cycle 2, oral methylprednisolone was added every other day stopping 48 h before and starting 48 h after each dexamethasone infusion. Results Overall response rate and clinical benefit rate were 63% and 79%, respectively. Progression free survival was 12.9 months. There were only 5 AEs of Grade ≥ 3 which included lymphocytopenia (13%), leukopenia (4%), and neutropenia (4%). No Grade ≥ 3 AE related to respiratory infection, anemia, or thrombocytopenia were reported. Conclusion This study shows that the two‐drug class combination of ISAdm is an effective and well tolerated treatment option for RRMM patients exhibiting only BP. | ||
| 700 | 1 | |a Jew, Scott |4 aut | |
| 700 | 1 | |a Goldwater, Marissa‐Skye |4 aut | |
| 700 | 1 | |a Beatty, Bethany Marie |4 aut | |
| 700 | 1 | |a Bujarski, Sean |4 aut | |
| 700 | 1 | |a ElSayed, Adam |4 aut | |
| 700 | 1 | |a Danis, Ryan |4 aut | |
| 700 | 1 | |a Kim, Susanna |4 aut | |
| 700 | 1 | |a Swift, Regina |4 aut | |
| 700 | 1 | |a Schwartz, Gary |4 aut | |
| 700 | 1 | |a Berenson, James R. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European Journal of Haematology |g 111(2023), 4, Seite 628-635 |w (DE-627)WLY004983017 |x 16000609 |7 nnns |
| 773 | 1 | 8 | |g volume:111 |g year:2023 |g number:4 |g pages:628-635 |g extent:8 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 951 | |a AR | ||
| 952 | |d 111 |j 2023 |e 4 |h 628-635 |g 8 | ||